GSK 4716
GSK 4716 性质
| 密度 | 1.12 |
|---|---|
| 储存条件 | Inert atmosphere,2-8°C |
| 溶解度 | 二甲基亚砜：>10mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 8.48±0.15(Predicted) |
| 颜色 | 白色至类白色 |
| InChI | 1S/C17H18N2O2/c1-12(2)14-5-3-13(4-6-14)11-18-19-17(21)15-7-9-16(20)10-8-15/h3-12,20H,1-2H3,(H,19,21)/b18-11+ |
| InChIKey | IKPPIUNQWSRCOZ-WOJGMQOQSA-N |
| SMILES | CC(C)c1ccc(cc1)\C=N\NC(=O)c2ccc(O)cc2 |
GSK 4716 用途与合成方法
ERRβ/γ
Treatment of differentiated C2C12 cells with the ERRβ/γ agonist (relative to vehicle) over a 2 to 4 h time period reveals a reproducible and robust increase in the immunoreactivity of the GRα-D isoform. It is observed that MAO-A mRNA expression is significantly increased by treatment with the ERRβ/γ agonist, GSK4716. Furthermore, it is observed that GSK4716 induces the expression of the mRNAs encoding peroxisome proliferator-activated receptor-γcoactivator 1α (PGC-1α) and PGC-1β (key regulator of many metabolic genes) identified as direct coactivators for the ERR family. GSK4716 induces the expression of PGC-1 and genes involved in fatty acid oxidation in concordance with the characterized role of ERRγ in cardiac metabolism. Treatment of primary mouse myotubes with GSK4716, an ERRβ/γ agonist, results in a concerted increase in the expression levels of Ppargc1a , Ppargc1b , and the Esrr genes. Furthermore, Cpt1b , Atp5b , and Idh3 , genes in key mitochondrial pathways, are also induced by GSK4716. Additionally, GSK4716 increases citrate synthase activity and cytochrome c protein levels.
安全信息
| 危险品标志 | Xi,N |
|---|---|
| 危险类别码 | 43-50/53 |
| 安全说明 | 36/37-60-61 |
| 危险品运输编号 | UN 3077 9 / PGIII |
| WGK Germany | 3 |
| 危险等级 | 9 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 危害水生环境-急性危害 类别1 危害水生环境-长期危害 类别1 皮肤致敏物 类别1 |
GSK 4716 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-03-03 | S0358 | GSK 4716 | 101574-65-6 | 5mg | 4479.93 |
| 2026-03-03 | S0358 | GSK 4716 | 101574-65-6 | 25mg | 13505.3 |
